<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868816</url>
  </required_header>
  <id_info>
    <org_study_id>2009-02</org_study_id>
    <nct_id>NCT00868816</nct_id>
  </id_info>
  <brief_title>Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles</brief_title>
  <official_title>A Prospective, Randomized, Control Trial of Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles vs 12 Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate which oxaliplatie based adjuvant method (8 cycles
      or 12 cycles) is better for patients receiving curative colorectal cancer resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We administered 5-FU, lv and Oxaliplatin as adjuvant chemotherapy (3 weeks per cycle) to
      patients with Stage II or Stage III colorectal cancer. The study endpoints were disease-free
      survival, overall survival, and liver metastasis-free survival as evaluated by
      intent-to-treat analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 years after operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival liver metastasis-free survival</measure>
    <time_frame>5 years after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 cycles of oxaliplatine based adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 cycles of oxaliplatine based adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12 cycles of oxaliplatine based adjuvant chemotherapy</intervention_name>
    <description>oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8 cycles of oxaliplatine based adjuvant chemotherapy</intervention_name>
    <description>oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &lt; 75 years with histologically proven adenocarcinoma of the colon or rectum

          -  no severe major organ dysfunction

          -  WHO performance status of 0 or 1

          -  Stage II (T3-4, N0, M0) or Stage III (T0-4, N1-2, M0) disease (according to the 1997
             revision of the International Union Against Cancer TNM staging system)

        Exclusion Criteria:

          -  age &gt;= 75

          -  severe major organ dysfunction

          -  WHO performance status of &gt;1

          -  Stage I or Stage IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianmin xu, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>department of general surgery, zhongshan hospital, fudan university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>xu jianmin</name_title>
    <organization>zhongshan hospital, fudan university</organization>
  </responsible_party>
  <keyword>oxaliplatine</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

